Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sacituzumab Tirumotecan to Treat Patients With Brain Metastases From Triple-negative Breast Cancer

NCT07458113 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT07458113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07458113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sacituzumab Tirumotecan to Treat Patients With Brain Metastases From Triple-negative Breast Cancer
Lead sponsor
Yale University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
August 31, 2029
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic triple negative breast cancers